{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:34:19Z","timestamp":1793136859670,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.nucmedbio.2018.05.002","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T11:59:05Z","timestamp":1525521545000},"page":"18-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors"],"prefix":"10.1016","volume":"62-63","author":[{"given":"Ganesan","family":"Vaidyanathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choong Mo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"McDougald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il","family":"Minn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9648-6153","authenticated-orcid":false,"given":"Mary","family":"Brummet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zalutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymeth.2017.07.009","article-title":"New aspects of molecular imaging in prostate cancer","author":"Ceci","year":"2017","journal-title":"Methods"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0010","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s13139-016-0439-4","article-title":"Influence of androgen deprivation therapy on the uptake of PSMA-targeted agents: emerging opportunities and challenges","volume":"51","author":"Bakht","year":"2017","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0020","doi-asserted-by":"crossref","first-page":"168","DOI":"10.23736\/S1824-4785.17.02977-6","article-title":"Radiolabeled prostate-specific membrane antigen small-molecule inhibitors","volume":"61","author":"Will","year":"2017","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.cpet.2016.12.001","article-title":"Imaging of prostate cancer using 64Cu-labeled prostate-specific membrane antigen ligand","volume":"12","author":"Singh","year":"2017","journal-title":"PET Clin"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0030","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00259-016-3609-9","article-title":"The 68Ga\/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates","volume":"44","author":"Scarpa","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0035","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cpet.2016.12.004","article-title":"Gallium-68 prostate-specific membrane antigen PET imaging","volume":"12","author":"Hofman","year":"2017","journal-title":"PET Clin"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0045","first-page":"67","article-title":"213Bi-labeled prostate-specific membrane antigen-targeting agents induce DNA double-strand breaks in prostate cancer xenografts","volume":"32","author":"Nonnekens","year":"2017","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0050","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1021\/acs.jmedchem.5b01268","article-title":"[18F]Fluorobenzoyllysinepentanedioic acid carbamates: new scaffolds for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)","volume":"59","author":"Yang","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0055","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.urology.2007.03.025","article-title":"Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms","volume":"70","author":"Baccala","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0060","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1007\/s00259-017-3737-x","article-title":"Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis","volume":"44","author":"Klein Nulent","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0065","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1021\/jm950801q","article-title":"Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase","volume":"39","author":"Jackson","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0070","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2967\/jnumed.114.147181","article-title":"PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer","volume":"56","author":"Kratochwil","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0075","doi-asserted-by":"crossref","first-page":"849","DOI":"10.7150\/thno.14744","article-title":"Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent","volume":"6","author":"Chatalic","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0080","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2967\/jnumed.112.114512","article-title":"Pharmacokinetic properties of peptidic radiopharmaceuticals: reduced uptake of (EH)3-conjugates in important organs","volume":"54","author":"Eder","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0085","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1021\/acs.bioconjchem.7b00458","article-title":"Improving the imaging contrast of 68Ga-PSMA-11 by targeted linker design: charged spacer moieties enhance the pharmacokinetic properties","volume":"28","author":"Baranski","year":"2017","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0090","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.addr.2008.04.005","article-title":"Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins","volume":"60","author":"Akizawa","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0095","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","article-title":"Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention","volume":"51","author":"Vegt","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0100","first-page":"128","article-title":"Chemical design of radiolabeled antibody fragments for low renal radioactivity levels","volume":"59","author":"Arano","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0105","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00259-017-3791-4","article-title":"Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results","volume":"44","author":"Matteucci","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0110","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.1021\/jm801055h","article-title":"Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer","volume":"51","author":"Chen","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0115","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2967\/jnumed.116.174300","article-title":"(2S)\u20112\u2011(3\u2011(1\u2011carboxy\u20115\u20114\u2011[211At]\u2011astatobenzamido)pentyl)ureido)\u2011pentanedioic acid for PSMA-targeted \u03b1-particle radiopharmaceutical therapy","volume":"57","author":"Kiess","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nucmedbio.2010.07.006","article-title":"Radioiodinated O6-benzylguanine derivatives containing an azido function","volume":"38","author":"Vaidyanathan","year":"2011","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0125","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3390\/molecules20022081","article-title":"Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging","volume":"20","author":"Meletta","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0130","first-page":"1508","article-title":"High-level production of \u03b1-particle-emitting 211At and preparation of 211At-labeled antibodies for clinical use","volume":"42","author":"Zalutsky","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0135","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2967\/jnumed.106.038505","article-title":"Radiopharmaceutical chemistry of targeted radiotherapeutics, part 3: \u03b1-particle-induced radiolytic effects on the chemical behavior of 211At","volume":"48","author":"Pozzi","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0140","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm800994j","article-title":"A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer","volume":"52","author":"Maresca","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0145","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","article-title":"Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors","volume":"59","author":"Benesova","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0150","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nucmedbio.2017.10.001","article-title":"Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: stability and complexation kinetics of 68Ga3+, 111In3+, 177Lu3+ and 225Ac3+","volume":"55","author":"Kelly","year":"2017","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0155","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/0969-8043(94)90230-5","article-title":"Direct n.c.a. electrophilic radioiodination of tyrosine analogues; their in vivo stability and brain-uptake in mice","volume":"45","author":"Krummeich","year":"1994","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0160","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1042\/bj2090251","article-title":"Certain mouse strains are deficient in a kidney brush-border metallo-endopeptidase activity","volume":"209","author":"Bond","year":"1983","journal-title":"Biochem J"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0165","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1021\/jm400823w","article-title":"Effect of chelators on the pharmacokinetics of 99mTc-labeled imaging agents for the prostate-specific membrane antigen (PSMA)","volume":"56","author":"Ray Banerjee","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0170","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1021\/bc025565u","article-title":"Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a cys-diabody","volume":"13","author":"Li","year":"2002","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0175","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2967\/jnumed.111.091256","article-title":"In vivo near-infrared fluorescence imaging of integrin \u03b12\u03b21 in prostate cancer with cell-penetrating-peptide-conjugated DGEA probe","volume":"52","author":"Huang","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0180","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.nucmedbio.2013.06.012","article-title":"Synthesis and preclinical characterization of [64Cu]NODAGA-MAL-exendin-4 with a N\u03b5-maleoyl-l-lysyl-glycine linkage","volume":"40","author":"Yim","year":"2013","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0185","doi-asserted-by":"crossref","first-page":"7890","DOI":"10.1021\/jm400895s","article-title":"Preparation of asymmetric urea derivatives that target prostate-specific membrane antigen for SPECT imaging","volume":"56","author":"Harada","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.05.002_bb0190","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1021\/bc300428b","article-title":"Renal brush border enzyme-cleavable linkages for low renal radioactivity levels of radiolabeled antibody fragments","volume":"24","author":"Akizawa","year":"2013","journal-title":"Bioconjug Chem"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805118301069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805118301069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:28:28Z","timestamp":1760848108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805118301069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":38,"alternative-id":["S0969805118301069"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2018.05.002","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2018.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}